Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Change And More Change: That’s What Brexit Means For Drug Companies

Executive Summary

The EU medicines network has issued a long list of changes that drug companies with activities in the UK will have to make if they are to continue to be located from a regulatory standpoint in the European Economic Area following Brexit. Aspects affected include the location of orphan designation holders, qualified persons for pharmacovigilance, companies’ manufacturing and batch release sites and maintenance of SME status.

You may also be interested in...

Ireland Fears Shortage Of Medicines Co-Labeled With UK Following Brexit

By encouraging and facilitating the joint labeling of medicines with the UK, Ireland has ensured the availability of the necessary human and veterinary medicines despite its small market size. But Brexit is causing concern that medicines for smaller patient populations may not be commercially viable if they have to be packaged separately for the Irish market.

Industry Response To Brexit Survey Key For Future Planning, Says EMA

Sponsors of centrally authorized medicines in the EU are being urged to respond to a survey by the European Medicines Agency aimed at gauging industry's preparedness for Brexit. Companies have until Feb. 9 to complete survey, which the EMA says is critical to help with resource planning and ensuring a smooth transition.

EMA Explains How To Make Brexit-Related MA Changes, As Industry Bodies Urge Transition Period

The EMA has produced further guidance for pharmaceutical companies on the changes they will need to make as a result of Brexit, focusing on activities such as transfers of marketing authorizations and orphan designations, and changes to personnel responsible for pharmacovigilance and batch recalls. Meanwhile, UK and European industry bodies say there is not enough time to make the necessary changes and that a transition period is needed.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts